Media center

We provide ongoing updates on our commercial, clinical and financial progress through regular press releases, presentations and webcasts, which can be accessed through the company’s media center.

Press Releases

Circassia to Exercise Option for Full US Commercial Rights to COPD Treatment Tudorza® from AstraZeneca

Click here to download the full press release Oxford, UK – 11 December 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces it has...

Interim Results for the Six Months Ended 30 June 2018

Click here to download the full 2018 interim results – NIOX® sales growth continued – – Tudorza® profit share revenues increased – – Duaklir® NDA and Tudorza® sNDA accepted for review by FDA – –...

Circassia Announces Duaklir® New Drug Application (NDA) and Tudorza® Supplemental NDA Accepted for Review by FDA

Click here to download full press release – PDUFA target action date of 31 March 2019 confirmed for both filings – Oxford, UK – 13 August 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR),...
More press releases

In this section

Press releases

Presentations

Webcasts & audio

Image library

Media contacts